Zidovudine

證據等級: L5

預測適應症: 6 個

Before the report, one editorial note on how I handled a structural mismatch in this specific pack: predicted_indications contains 6 ranked diseases, and array position [0] ("feline acquired immunodeficiency syndrome") is a veterinary/animal-model finding, not a human indication — its own repurposing_rationale explicitly says so. Rather than silently forcing a human-drug report around a cat disease, I followed the template's literal extraction rules for the required fields (so the Quick Overview reflects predicted_indications[0] as instructed), but added a supplementary comparison table so the reviewer can see all 6 predictions and their wildly different evidence quality (2 non-human models, 2 zero-evidence/likely false positives, 2 with real L1 human trial evidence that actually just restate zidovudine's original approved use). This is flagged transparently in the report rather than guessed away.

Zidovudine: From HIV/AIDS Treatment to Feline Acquired Immunodeficiency Syndrome (Veterinary Model)

One-Sentence Summary

Zidovudine (AZT) is the original nucleoside reverse transcriptase inhibitor (NRTI), established since 1987 as an antiretroviral for HIV infection/AIDS. The top-ranked TxGNN prediction in this evidence pack is Feline Acquired Immunodeficiency Syndrome — a veterinary, cross-species model finding (score 99.96%) — supported only by 20 animal-study publications and 0 human clinical trials. This pack additionally contains 5 other predictions, including two (AIDS-related complex, congenital HIV) with strong human trial evidence, but these largely restate zidovudine's already-established indication rather than a genuinely new repurposing target — see "Other Predicted Indications" below.

Quick Overview

Item	Content
Original Indication	HIV infection / AIDS (antiretroviral therapy) — inferred from repurposing-rationale text in this pack; not separately listed in the regulatory record (New Zealand: unmarketed, 0 licenses on file)
Predicted New Indication	Feline Acquired Immunodeficiency Syndrome (veterinary/animal-model indication)
TxGNN Prediction Score	99.96%
Evidence Level	L3
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, a structured mechanism-of-action (MOA) record is not available for this drug in the evidence pack (flagged as a High-severity data gap, DG002). Based on the mechanistic descriptions embedded in this pack's own repurposing rationale, zidovudine is a thymidine nucleoside analogue: it is phosphorylated intracellularly to its active triphosphate form, which competitively inhibits HIV-1 reverse transcriptase and causes premature viral DNA chain termination, blocking retroviral replication.

Feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) are both retroviruses (lentivirus/oncovirus) whose reverse transcriptase is structurally homologous to HIV-1's. The theoretical rationale is that a nucleoside analogue built to block HIV-1 RT should, in principle, cross-inhibit these related retroviral enzymes in cats.

However, this is explicitly a cross-species animal model/veterinary indication, not a human clinical indication, and the evidence pack itself flags that it does not fit the target population of a human drug-repurposing pipeline. It should be labeled clearly as a veterinary research question rather than a candidate for human regulatory advancement.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2178336	1990	Prospective Animal Trial	Antimicrobial Agents and Chemotherapy	AZT + interferon-alpha 2b in presymptomatic FeLV-induced immunodeficiency (FAIDS); combination showed antiviral benefit over AZT alone
2164083	1990	Prospective Animal Trial	J Acquired Immune Deficiency Syndromes	AZT + IFN-α + IL-2 prophylaxis for FeLV-FAIDS; AZT inhibited FeLV replication in vitro, ~25–30% added effect with IFN-α
8381867	1993	Prospective Animal Trial	J Acquired Immune Deficiency Syndromes	Prophylactic AZT (30 mg/kg/day) prevented early viremia and lymphocyte decline in FIV-inoculated cats, but did not prevent primary infection
2475068	1989	Review/Model Description	Antimicrobial Agents and Chemotherapy	Establishes FIV as a reverse-transcriptase-homologous model justifying AZT-based chemotherapy research for AIDS
18550661	2008	Genetic/Phylogenetic Analysis	Journal of Virology	Phylogenetic analysis of FIV gag/pol/env genes in AZT-treated vs. treatment-naïve cats in Brazil
7688949	1993	Cohort (feline)	Archives of Virology	AZT and cyclosporine both lowered plasma FIV titers at 2 weeks post-infection; effect not sustained
7618256	1995	Animal Study (SCID mouse model)	Veterinary Immunology and Immunopathology	AZT reduced proviral burden and enhanced humoral immune response in SCID-feline mouse FIV model
9226004	1997	Preclinical/Drug Delivery Study	Journal of Leukocyte Biology	Erythrocyte-based targeted delivery system for phosphorylated nucleoside analogues (AZT-class) to macrophages, an HIV reservoir cell
15047505	2004	Animal Study	Antimicrobial Agents and Chemotherapy	Topical AZT-derivative spermicide (WHI-07) prevented vaginal/rectal FIV transmission in cats
8399067	1993	Animal Study	J Immunotherapy	AZT combined with adoptive lymphocyte transfer and IFN-α reversed FeLV infection in cats

Other Predicted Indications in This Evidence Pack

This pack scored 6 diseases for zidovudine. Because the evidence quality and clinical relevance vary enormously between them, they are summarized here for full transparency rather than omitted:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Decision Stage	Recommendation	Note
1	Feline Acquired Immunodeficiency Syndrome	99.96%	L3	S1	Research Question	Veterinary/animal model only (see main body above)
2	Simian Immunodeficiency Virus Infection	99.96%	L3	S1	Research Question	Non-human primate model; validates HIV-RT mechanism, not a human indication
3	Neurodevelopmental disorder with ataxic gait, absent speech, decreased cortical white matter	99.96%	L5	S0	Hold	0 trials, 0 literature; purely theoretical LINE-1/interferon-pathway hypothesis
4	Obsolete familial combined hyperlipidemia	99.62%	L5	S0	Hold	0 trials, 0 literature; mechanistically contradictory — NRTIs are known to cause dyslipidemia, not treat it; disease term is itself flagged "obsolete" in the ontology — likely a false-positive/data-noise prediction
5	AIDS Related Complex	99.19%	L1	S3	Proceed with Guardrails	50 clinical trials, 20 publications, including the pivotal 1987 Fischl et al. placebo-controlled RCT (NEJM, PMID 3299089) that established AZT as the first approved anti-HIV drug — this is zidovudine's original indication, not a new one
6	Congenital Human Immunodeficiency Virus	99.19%	L1	S3	Proceed with Guardrails	33 clinical trials, 20 publications, anchored by PACTG 076-era studies (e.g. NCT00386230) establishing AZT for prevention of mother-to-child HIV transmission — an established, guideline-endorsed use since 1994, not a novel repurposing target

Interpretation: none of the 6 predictions in this pack represent a genuinely new, actionable human repurposing indication for zidovudine. Ranks 1–2 are non-human models; ranks 3–4 have no supporting evidence at all and rank 4 is likely a database/ontology artifact; ranks 5–6 have strong evidence but simply rediscover the drug's own original approved indication.

New Zealand Market Information

Zidovudine currently has no marketing authorization on file in New Zealand (0 licenses; market status: Not Marketed). No product, dosage form, or approved-indication records are available to summarize.

Safety Considerations

Structured safety data (key warnings, contraindications, drug–drug interactions) could not be retrieved for this evidence pack. This is recorded as a Blocking-severity data gap (DG001 — TFDA/Medsafe package insert warnings/contraindications not yet extracted), which by definition prevents this candidate from completing the S1 safety pre-assessment stage.

Please refer to the package insert for safety information once retrieved.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication in this pack (feline acquired immunodeficiency syndrome) is a veterinary cross-species model finding with no human clinical trial support (L3, Research Question stage) — it does not represent an actionable human repurposing candidate. The other predictions in this pack are similarly non-actionable: two are non-human primate models, two have zero supporting evidence (one likely a false positive), and the two with genuine L1 human trial evidence (AIDS-related complex, congenital HIV) merely restate zidovudine's own original, already-approved antiretroviral indication rather than constituting a new use.

To proceed, the following is needed:

TFDA/Medsafe package insert data (warnings, contraindications) — currently a Blocking gap (DG001)
Structured mechanism-of-action documentation (DG002)
A pipeline-level review to exclude non-human (veterinary/primate model) predictions from the human drug-repurposing evaluation queue, or route them to a separate veterinary-use track
Re-scoring/filtering to prevent "re-discovery" of a drug's own original indication (ranks 5–6) from being reported as a novel repurposing signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.